Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024. In the quarter to June 2026, revenue grew 14.9%, EPS fell 24.8%, free cash flow grew 10.8% and total debt fell 9.90%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.

320.86 0.34 −0.11%
Market cap
$12.7B
P/E
78.4×
Fwd P/E
63.5×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 7 8 8

+8 more TTM periods

ROE
11.37% 12.73% 13.78% 13.32%
ROA
8.80% 9.80% 10.58% 10.18%
ROIC
13.13% 13.32% 13.09% 11.87%
Return on Tangible Assets
12.77% 14.28% 15.44% 15.33%
Average Days of Receivables
46.18 46.00 49.41 50.20
Free Cash Flow per Share
5.49 5.42 4.49 3.91
Free Cash Flow
215.91 212.73 174.93 152.62
Other line items

Show all line items

Columns are period end dates